Tracking GLP-1 Side Effects: What to Log & Why

Tracking GLP-1 side effects means keeping a dated, severity-rated log of how you feel, so you and your provider can see patterns instead of guessing. The essentials to log are the gastrointestinal symptoms (nausea, vomiting, constipation, diarrhea, reflux), your appetite, your energy, and, importantly, your strength and exercise performance, because falling strength and persistent fatigue can be early warnings of muscle loss rather than ordinary drug side effects. A good log makes dose conversations faster and your decisions better informed.

This guide covers exactly what to log, how to log it, and why the muscle-side signals (strength and fatigue) belong in your symptom journal right next to the nausea.

Why track side effects at all

GLP-1 medications like Ozempic or Wegovy (semaglutide) and Zepbound or Mounjaro (tirzepatide) work by suppressing appetite and slowing digestion, which is also why their most common side effects are gastrointestinal. Those effects often shift as your dose changes and as your body adjusts, so what you feel in week 2 may be very different from week 12.

A symptom log turns that moving target into something you can actually read. It does three things: it reveals your personal tolerance pattern, it gives your provider a clear timeline to make dose decisions from, and (the part most people miss) it lets you separate a normal drug side effect from an early sign that you are losing muscle. None of that is possible from memory alone.

What to log: the core symptoms

Start with the classic GLP-1 side effects. For each, record the severity (a 0 to 10 scale works well) and the date so you can line it up against your dose:

• Nausea. The most common GLP-1 side effect and the one most likely to track your dose week.
• Vomiting. Less common than nausea but more important to flag if it persists, given dehydration risk.
• Constipation and diarrhea. GI motility changes both ways; note which and how severe.
• Reflux or heartburn. Slowed stomach emptying can worsen reflux for some people.
• Early satiety and bloating. How quickly you feel full, and whether food "sits."

These are the symptoms most likely to drive a dose hold or adjustment, and the most useful to show a provider as a trend rather than a one-off complaint. Logging them against your injection schedule also reveals whether your symptoms cluster around dose day, which connects to the GLP-1 dose week and PK curve.

Severity is what makes this data usable. "I had some nausea" and "nausea so bad I couldn't eat for two days" are different facts that lead to different decisions, and a 0 to 10 rating captures the gap. Most GLP-1 GI side effects are mild to moderate and tend to ease as your body adjusts or after a titration step, but the only way to know whether yours are following that expected path (or trending the wrong way) is to have a record you can look back on rather than a fuzzy memory of "a rough couple of weeks."

What to log: appetite and energy

Two more signals deserve their own tracking because they shape everything else:

• Appetite. Rate how strong your appetite is. This matters beyond comfort: appetite suppression is the mechanism by which GLP-1 drugs reduce intake, and research suggests caloric intake can fall by roughly 16 to 39 percent. When appetite is lowest, your protein intake is most at risk, and protein is the main lever protecting your muscle.
• Energy. General energy and mood. Low energy can come from the drug, from eating too little overall, or from both. Tracking it over time, against your dose and your food intake, is how you start to tell which.

Appetite in particular is worth logging daily, because it tends to move across the dosing week and tells you which days you need to plan protein around. The protein guide covers how much you actually need.

The signal most people miss: strength and fatigue

Here is the part that makes a GLP-1 symptom log different from a generic side-effect tracker. You should log strength and fatigue, because together they are an early-warning system for muscle loss.

On a GLP-1, weight comes off fast, and research suggests roughly 25 to 40 percent of it can be lean mass (tirzepatide nearer 25 percent in the SURMOUNT-1 DEXA substudy, some semaglutide trials near 40 percent in SUSTAIN 8 and STEP 1). "Lean mass" includes water and organs, so it is not all skeletal muscle, but a meaningful share is. The problem is that muscle loss is invisible day to day; you do not feel a gram leave.

What you can feel is the consequence: workouts getting harder, lifts dropping, grip weakening, recovery slowing, a persistent flatness that does not lift. So log:

• Strength or performance. Pick one or two benchmarks (the weight you lift for a set, push-ups to failure, or grip if you have a dynamometer) and record them weekly.
• Fatigue. Rate it, and note whether it is the "tired but fine" kind or the "weaker than I was" kind.

Now the key move: read fatigue next to your protein intake. Fatigue is a recognized drug side effect, but persistent weakness alongside chronically low protein points toward muscle loss instead. A 2025 study found fewer than half of GLP-1 users hit the minimum recommended protein target of about 1.2 g/kg/day, so under-eating protein is common, not rare. When your fatigue lines up with falling protein and falling strength, that is a muscle-loss signal, not just a side effect. The signs of muscle loss on a GLP-1 covers the rest of the pattern.

How to log it so the data is actually useful

A pile of notes is not a log. To make your tracking pay off:

1. Use a consistent severity scale. A 0 to 10 rating for each symptom makes changes comparable over weeks.
2. Always record the date, and ideally the dose. A symptom means little without knowing where you were in your dose cycle and at what dose level.
3. Log daily for fast-moving signals (nausea, appetite, energy) and weekly for slower ones (strength benchmarks, weight, body composition).
4. Add short notes. "Nausea worse after big dinner" or "skipped protein, felt flat" is the context that turns numbers into insight.
5. Keep it all in one place. Symptoms, doses, protein, and strength scattered across apps cannot be correlated.

That last point is the whole reason to use a dedicated tool. In Myo, side effects (11 symptoms rated 0 to 10, plus notes) sit right next to your strength and lean-mass trends, so when "fatigue" lines up with falling protein and falling strength, you can tell a real side effect from a muscle-loss warning instead of guessing. Logging side effects, daily check-ins, and protein is part of the free tier; the side-effect correlation charts and the muscle-loss trend flag are Premium. Myo is a tracking and education tool, not medical advice, and it does not adjust your medication; it just makes the pattern visible.

Bringing it to your provider

The payoff of all this logging shows up at your appointment. A dated symptom log lined up against your dose history turns a vague "I've been feeling rough" into a timeline your provider can actually act on, which speeds up the visit and makes dose decisions better informed. Myo can generate a doctor-ready PDF or CSV (a Premium feature) so you walk in with the data instead of trying to reconstruct three months from memory. This connects naturally to tracking your injections and schedule, since a clean dose log is the backbone everything else correlates against.

One caution that overrides all of the above: tracking is not a substitute for medical care. Anything severe, persistent, or alarming (signs of pancreatitis, gallbladder problems, severe dehydration, or a reaction that worries you) warrants prompt medical advice, not a wait-and-log. The journal is there to make your care better, not to replace it.

The bottom line

Log the GI symptoms, appetite, and energy, and add strength and fatigue so your journal can catch muscle loss the scale and the nausea chart would miss. Rate severity, always date it, keep it in one place, and read fatigue next to your protein and strength. Done that way, a side-effect log stops being a chore and becomes the clearest signal you have about how your GLP-1 is really treating you.

References

• Appetite suppression and caloric intake reduction; mechanism of muscle loss: Mass General (advances.massgeneral.org/endocrinology, id=1601); PMC12264624 joint advisory.
• Lean-mass loss range on GLP-1s: Tirzepatide SURMOUNT-1 DEXA substudy, Diabetes, Obesity and Metabolism, 2025 (doi:10.1111/dom.16275); Semaglutide SUSTAIN 8, 2020 (PMC6997246); STEP 1 DXA analysis, Journal of the Endocrine Society, 2021.
• Protein intake shortfall in GLP-1 users: Johnson et al., 2025 (PMC12419545), fewer than half hitting 1.2 g/kg/day.
• Protein target during weight loss: OMA/TOS/ACLM/ASN 2025 joint advisory (PMC12264624).